Veradigm (MDRX) Competitors

$4.65 +0.19 (+4.26%)

As of 09:30 AM Eastern

MDRX vs. OMCL, HSTM, CNGL, FUSE, and OMQS

Should you be buying Veradigm stock or one of its competitors? The main competitors of Veradigm include Omnicell (OMCL), HealthStream (HSTM), Canna-Global Acquisition (CNGL), Fusemachines (FUSE), and OMNIQ (OMQS).

How does Veradigm compare to Omnicell?

Omnicell (NASDAQ:OMCL) and Veradigm (NASDAQ:MDRX) are both small-cap health care technology companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

In the previous week, Omnicell had 4 more articles in the media than Veradigm. MarketBeat recorded 6 mentions for Omnicell and 2 mentions for Veradigm. Omnicell's average media sentiment score of 0.93 beat Veradigm's score of 0.52 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradigm	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.7% of Omnicell shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Comparatively, 2.3% of Veradigm shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Omnicell has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
Veradigm	N/A	N/A	N/A

Omnicell presently has a consensus price target of $59.86, suggesting a potential upside of 39.20%. Given Omnicell's stronger consensus rating and higher probable upside, equities analysts clearly believe Omnicell is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Omnicell has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.65	$2.05M	$0.44	97.73
Veradigm	$1.53B	0.37	N/A	N/A	N/A

Summary

Omnicell beats Veradigm on 14 of the 15 factors compared between the two stocks.

How does Veradigm compare to HealthStream?

HealthStream (NASDAQ:HSTM) and Veradigm (NASDAQ:MDRX) are both small-cap health care technology companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

HealthStream has a net margin of 6.39% compared to Veradigm's net margin of 0.00%. HealthStream's return on equity of 6.47% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthStream	6.39%	6.47%	4.44%
Veradigm	N/A	N/A	N/A

69.6% of HealthStream shares are held by institutional investors. 20.4% of HealthStream shares are held by insiders. Comparatively, 2.3% of Veradigm shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HealthStream has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthStream	$304.06M	2.25	$18.34M	$0.67	34.98
Veradigm	$1.53B	0.37	N/A	N/A	N/A

HealthStream has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

HealthStream currently has a consensus price target of $24.00, suggesting a potential upside of 2.41%. Given HealthStream's stronger consensus rating and higher possible upside, research analysts clearly believe HealthStream is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, HealthStream had 8 more articles in the media than Veradigm. MarketBeat recorded 10 mentions for HealthStream and 2 mentions for Veradigm. Veradigm's average media sentiment score of 0.52 beat HealthStream's score of 0.52 indicating that Veradigm is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthStream	1 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradigm	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

HealthStream beats Veradigm on 10 of the 13 factors compared between the two stocks.

How does Veradigm compare to Canna-Global Acquisition?

Veradigm (NASDAQ:MDRX) and Canna-Global Acquisition (NASDAQ:CNGL) are both small-cap business services companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

In the previous week, Veradigm had 2 more articles in the media than Canna-Global Acquisition. MarketBeat recorded 2 mentions for Veradigm and 0 mentions for Canna-Global Acquisition. Veradigm's average media sentiment score of 0.52 beat Canna-Global Acquisition's score of 0.00 indicating that Veradigm is being referred to more favorably in the media.

Company	Overall Sentiment
Veradigm	Positive
Canna-Global Acquisition	Neutral

19.5% of Canna-Global Acquisition shares are owned by institutional investors. 2.3% of Veradigm shares are owned by company insiders. Comparatively, 72.1% of Canna-Global Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Veradigm has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Canna-Global Acquisition has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Canna-Global Acquisition	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.37	N/A	N/A	N/A
Canna-Global Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Veradigm beats Canna-Global Acquisition on 4 of the 6 factors compared between the two stocks.

How does Veradigm compare to Fusemachines?

Veradigm (NASDAQ:MDRX) and Fusemachines (NASDAQ:FUSE) are both small-cap computer integrated systems design industry companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fusemachines	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Veradigm has higher revenue and earnings than Fusemachines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.37	N/A	N/A	N/A
Fusemachines	$7.71M	5.19	-$930K	N/A	N/A

46.8% of Fusemachines shares are owned by institutional investors. 2.3% of Veradigm shares are owned by insiders. Comparatively, 83.0% of Fusemachines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Fusemachines	N/A	N/A	N/A

Veradigm has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Fusemachines has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

In the previous week, Fusemachines had 1 more articles in the media than Veradigm. MarketBeat recorded 3 mentions for Fusemachines and 2 mentions for Veradigm. Fusemachines' average media sentiment score of 1.44 beat Veradigm's score of 0.52 indicating that Fusemachines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradigm	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fusemachines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fusemachines beats Veradigm on 7 of the 8 factors compared between the two stocks.

How does Veradigm compare to OMNIQ?

Veradigm (NASDAQ:MDRX) and OMNIQ (NASDAQ:OMQS) are both small-cap computer integrated systems design industry companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Veradigm has a net margin of 0.00% compared to OMNIQ's net margin of -34.33%.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
OMNIQ	-34.33%	N/A	-61.97%

Veradigm has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, OMNIQ has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

In the previous week, Veradigm had 2 more articles in the media than OMNIQ. MarketBeat recorded 2 mentions for Veradigm and 0 mentions for OMNIQ. Veradigm's average media sentiment score of 0.52 beat OMNIQ's score of 0.00 indicating that Veradigm is being referred to more favorably in the media.

Company	Overall Sentiment
Veradigm	Positive
OMNIQ	Neutral

5.7% of OMNIQ shares are held by institutional investors. 2.3% of Veradigm shares are held by company insiders. Comparatively, 11.6% of OMNIQ shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Veradigm has higher revenue and earnings than OMNIQ.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.37	N/A	N/A	N/A
OMNIQ	$81.19M	0.02	-$29.43M	-$0.38	N/A

Summary

Veradigm beats OMNIQ on 7 of the 10 factors compared between the two stocks.

Get Veradigm News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDRX vs. The Competition

Export

Metric	Veradigm	Computer integrated systems design Industry	Business Sector	NASDAQ Exchange
Market Cap	$559.86M	$910.32M	$6.36B	$12.14B
Dividend Yield	N/A	3.99%	3.07%	5.23%
P/E Ratio	23.25	2.11	30.77	25.38
Price / Sales	0.37	1.40	440.98	75.53
Price / Cash	N/A	N/A	22.61	36.29
Price / Book	N/A	N/A	6.12	6.65
Net Income	N/A	-$14.66M	$200.03M	$333.19M
7 Day Performance	-6.25%	-2.71%	-1.32%	-0.55%
1 Month Performance	3.33%	-1.51%	4.76%	7.66%
1 Year Performance	10.71%	-1.00%	40.00%	35.65%

Veradigm Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDRX Veradigm	N/A	$4.65 +4.3%	N/A	+8.1%	$559.86M	$1.53B	23.25	8,000	Gap Up
OMCL Omnicell	3.8879 of 5 stars	$43.44 +1.5%	$59.86 +37.8%	+67.3%	$1.95B	$1.18B	98.73	3,580	Analyst Upgrade
HSTM HealthStream	2.7777 of 5 stars	$21.25 +2.6%	$25.00 +17.6%	-17.0%	$609.62M	$304.06M	34.84	1,160	Analyst Upgrade
CNGL Canna-Global Acquisition	N/A	$9.00 flat	N/A	N/A	$59.49M	N/A	N/A	2
FUSE Fusemachines	1.3944 of 5 stars	$1.62 -4.7%	N/A	N/A	$49.19M	$7.71M	N/A	317	News Coverage Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDRX) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradigm (MDRX) Competitors

MDRX vs. OMCL, HSTM, CNGL, FUSE, and OMQS

How does Veradigm compare to Omnicell?

Summary

How does Veradigm compare to HealthStream?

Summary

How does Veradigm compare to Canna-Global Acquisition?

Summary

How does Veradigm compare to Fusemachines?

Summary

How does Veradigm compare to OMNIQ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDRX vs. The Competition

Veradigm Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veradigm (MDRX) Competitors

MDRX vs. OMCL, HSTM, CNGL, FUSE, and OMQS

How does Veradigm compare to Omnicell?

Does the media prefer OMCL or MDRX?

Do insiders and institutionals believe in OMCL or MDRX?

Which has more risk and volatility, OMCL or MDRX?

Is OMCL or MDRX more profitable?

Do analysts prefer OMCL or MDRX?

Which has preferable earnings & valuation, OMCL or MDRX?

Summary

How does Veradigm compare to HealthStream?

Is HSTM or MDRX more profitable?

Do institutionals and insiders believe in HSTM or MDRX?

Which has higher earnings and valuation, HSTM or MDRX?

Which has more volatility & risk, HSTM or MDRX?

Do analysts prefer HSTM or MDRX?

Does the media prefer HSTM or MDRX?

Summary

How does Veradigm compare to Canna-Global Acquisition?

Does the media favor MDRX or CNGL?

Do institutionals & insiders believe in MDRX or CNGL?

Which has more volatility & risk, MDRX or CNGL?

Is MDRX or CNGL more profitable?

Which has stronger valuation and earnings, MDRX or CNGL?

Summary

How does Veradigm compare to Fusemachines?

Do analysts recommend MDRX or FUSE?

Which has stronger earnings & valuation, MDRX or FUSE?

Do institutionals and insiders have more ownership in MDRX or FUSE?

Is MDRX or FUSE more profitable?

Which has more risk & volatility, MDRX or FUSE?

Does the media favor MDRX or FUSE?

Summary

How does Veradigm compare to OMNIQ?

Is MDRX or OMQS more profitable?

Which has more risk and volatility, MDRX or OMQS?

Does the media favor MDRX or OMQS?

Do institutionals and insiders have more ownership in MDRX or OMQS?

Which has higher valuation & earnings, MDRX or OMQS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDRX vs. The Competition

Veradigm Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools